Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SYN's Cash to Debt is ranked higher than
84% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. SYN: No Debt )
SYN' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: No Debt

Interest Coverage No Debt
SYN's Interest Coverage is ranked higher than
74% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SYN: No Debt )
SYN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 36.42
M-Score: -9.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -194.02
SYN's ROE (%) is ranked higher than
53% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. SYN: -194.02 )
SYN' s 10-Year ROE (%) Range
Min: -4484.82   Max: -48.04
Current: -194.02

-4484.82
-48.04
ROA (%) -176.09
SYN's ROA (%) is ranked higher than
50% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. SYN: -176.09 )
SYN' s 10-Year ROA (%) Range
Min: -1044.06   Max: -41.8
Current: -176.09

-1044.06
-41.8
ROC (Joel Greenblatt) (%) -2858.95
SYN's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. SYN: -2858.95 )
SYN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2835.38   Max: -179.08
Current: -2858.95

-2835.38
-179.08
Revenue Growth (%) -100.00
SYN's Revenue Growth (%) is ranked higher than
55% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. SYN: -100.00 )
SYN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -100
Current: -100

EBITDA Growth (%) 75.40
SYN's EBITDA Growth (%) is ranked higher than
98% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. SYN: 75.40 )
SYN' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 75.4
Current: 75.4

0
75.4
EPS Growth (%) 65.10
SYN's EPS Growth (%) is ranked higher than
98% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. SYN: 65.10 )
SYN' s 10-Year EPS Growth (%) Range
Min: 0   Max: 65.1
Current: 65.1

0
65.1
» SYN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SYN Guru Trades in Q4 2013

Chuck Royce 778,000 sh (+81.49%)
» More
Q1 2014

SYN Guru Trades in Q1 2014

Chuck Royce 276,000 sh (-64.52%)
» More
Q2 2014

SYN Guru Trades in Q2 2014

Chuck Royce 276,000 sh (unchged)
» More
Q3 2014

SYN Guru Trades in Q3 2014

Chuck Royce 276,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SYN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 28.70
SYN's P/B is ranked higher than
59% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. SYN: 28.70 )
SYN' s 10-Year P/B Range
Min: 1.67   Max: 28.7
Current: 28.7

1.67
28.7
EV-to-EBIT -6.83
SYN's EV-to-EBIT is ranked higher than
82% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SYN: -6.83 )
SYN' s 10-Year EV-to-EBIT Range
Min: -21.5   Max: -1.6
Current: -6.83

-21.5
-1.6
Current Ratio 4.74
SYN's Current Ratio is ranked higher than
73% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. SYN: 4.74 )
SYN' s 10-Year Current Ratio Range
Min: 0.03   Max: 58.44
Current: 4.74

0.03
58.44
Quick Ratio 4.74
SYN's Quick Ratio is ranked higher than
74% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. SYN: 4.74 )
SYN' s 10-Year Quick Ratio Range
Min: 0.03   Max: 58.44
Current: 4.74

0.03
58.44

Valuation & Return

vs
industry
vs
history
Price/Net Cash 43.00
SYN's Price/Net Cash is ranked higher than
75% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. SYN: 43.00 )
SYN' s 10-Year Price/Net Cash Range
Min: 0.72   Max: 42
Current: 43

0.72
42
Price/Net Current Asset Value 43.00
SYN's Price/Net Current Asset Value is ranked higher than
73% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. SYN: 43.00 )
SYN' s 10-Year Price/Net Current Asset Value Range
Min: 0.72   Max: 42
Current: 43

0.72
42
Price/Tangible Book 28.70
SYN's Price/Tangible Book is ranked higher than
64% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. SYN: 28.70 )
SYN' s 10-Year Price/Tangible Book Range
Min: 0.56   Max: 28
Current: 28.7

0.56
28
Earnings Yield (Greenblatt) -14.50
SYN's Earnings Yield (Greenblatt) is ranked higher than
60% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. SYN: -14.50 )
SYN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -14.5   Max: 0
Current: -14.5

-14.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SFYB.Germany
Synthetic Biologics Inc was incorporated in 1986 as Sheffield Pharmaceuticals, Inc. The Company is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases. Its developing an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome or C-IBS, an oral biologic to protect the gastrointestinal or GI microflora from the effects of intravenous or IV antibiotics for the prevention of Clostridium difficile or C. diff infection, a series of monoclonal antibodies or mAbs for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, it has two legacy programs. Its developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis or MS and cognitive dysfunction in MS. It also partnered the development of a treatment for fibromyalgia. Trimesta or oral estriol is being developed as an oral once-daily treatment for relapsing-remitting MS in women. Trimesta is also being developed for the treatment of cognitive dysfunction in female MS patients. This 12-month randomized, double-blind, placebo-controlled Phase II clinical trial is being conducted at UCLA. There are nine FDA-approved therapies for the treatment of relapsing-remitting MS: Betaseron, Rebif, Avonex, Copaxone, Tysabri, Gilenya, Extavia, Aubagio and Tecfidera. Effirma or flupirtine is being developed for the treatment of fibromyalgia by Meda AB. Current FDA-approved therapies for the treatment of C-IBS include AMITIZA or lubiprostone and LINZESS or linaclotide. The Company utilizes contract manufacturing firms to produce its investigational products Trimesta and SYN-004 in accordance with current good manufacturing processes or cGMP guidelines outlined by the FDA. It competes with Actelion Pharmaceuticals, Bayer Health Care, Biogen Idec, Eli Lilly & Co., Genzyme, GlaxoSmithKline Pharmaceuticals, Merck & Co., Pfizer, Novartis, Teva Pharmaceuticals and United Therapeutics, among others. The Company is subject to various government FDA, FTC, CPSC and USDA regulations.
» More Articles for AMEX:SYN

Headlines

Articles On GuruFocus.com
Synodon Inc. – A Breakthrough Technology For Pipeline Safety Jan 28 2013 

More From Other Websites
Synthetic Biologics Safe-to-Proceed Under IND to Initiate Clinical Trials of SYN-004 for the... Nov 24 2014
Synthetic Biologics Safe-to-Proceed Under IND to Initiate Clinical Trials of SYN-004 for the... Nov 24 2014
SYNTHETIC BIOLOGICS, INC. Financials Nov 21 2014
10-Q for Synthetic Biologics, Inc. Nov 17 2014
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 14 2014
Synthetic Biologics Reports Third Quarter 2014 Financial Results and Operational Highlights Nov 14 2014
Synthetic Biologics Reports Third Quarter 2014 Financial Results and Operational Highlights Nov 14 2014
Synthetic Biologics to Report Third Quarter 2014 Financial Results Nov 06 2014
Synthetic Biologics to Report Third Quarter 2014 Financial Results Nov 06 2014
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 03 2014
Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile... Oct 22 2014
Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile... Oct 22 2014
Synthetic Biologics Appoints Prominent Gastrointestinal (GI) Key Opinion Leaders to Irritable Bowel... Oct 15 2014
Synthetic Biologics Appoints Prominent Gastrointestinal (GI) Key Opinion Leaders to Irritable Bowel... Oct 15 2014
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Oct 10 2014
Synthetic Biologics to Raise $20.7 Million in Registered Direct Offering Oct 10 2014
Synthetic Biologics' SYN-005 Gets Orphan Drug Designation Sep 16 2014
Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome... Sep 16 2014
Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough... Sep 12 2014
Synthetic Biologics to Host Phase II Trimesta™ for Multiple Sclerosis Conference Call Sep 11 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK